Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Genetics clinical practice has paid limited attention to non-inherited aspects of cancer, namely mutations occurring during carcinogenesis. These somatic mutations are likely to be the primary determinants of cancer behaviour and treatment response, with a recent example being Her2/Neu gene status and response to Herceptin in breast cancer. AIM: To assess the feasibility of widespread testing of tumours by surveying UK histopathology and genetics laboratories. METHODS: The questionnaire asked: which of the common cancers or other malignancies are routinely assessed; which molecular and cytogenetic methods are used; who orders and funds testing; what is the future demand for somatic testing; and what are the barriers to widespread testing? RESULTS: Of 50 laboratories surveyed, 33 responded, 22 of which are currently using molecular tests. The survey shows that the most common tests are immunohistochemistry, fluorescence in-situ hybridisation and DNA testing of somatic mutations. Most laboratories predict testing will increase over the next 10 years, particularly for DNA testing using microarrays. Respondents perceived the main barriers to expanding molecular testing were a lack of laboratory funding and scientific evidence and testing not considered an NHS priority. CONCLUSION: These results provide important information for healthcare commissioners faced with managing demand for molecular testing of cancers.

Original publication

DOI

10.1136/jcp.2007.048819

Type

Journal

J Clin Pathol

Publication Date

03/2008

Volume

61

Pages

373 - 376

Keywords

Cytogenetics, Data Collection, Forecasting, Gene Expression Profiling, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Laboratories, Mutation, Neoplasms, Oligonucleotide Array Sequence Analysis, Research Support as Topic, United Kingdom